Thanks, this clears it up, sort of. I was confused in the proactive video because I was not understanding if the Meta analysis was to combine the data from brazil and the CD12 to get a Brazil approval of some sort, Or if the meta analysis was to combine the CD12 and future CD20 trials. I was unsure if the CD20 trial would not be needed if the Brazil trial fills that data. The comment that Cytodyn would ask for meta analysis from Brazil separately is interesting. I was kind of disappointed about the timeline to eve start another US trial, seems like it will take some time and nothing is set to go yet. However, if we only need to fill in specific missing data it might take very little time.